Chemomab Investor Relations - News

About
R&D
Pipeline
Investors
News
Contact

For Patients

Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני

Investor Relations

Investor Relations

Overview
News & Events
- News
- Events
- Presentations
- Contact IR
- Email Alerts
Financials & Filings
Stock
Corporate Governance

News
Events
Presentations
Contact IR
Email Alerts

Chemomab received OCS grant for the development of the CM101 program.

Investor Relations

Chemomab Therapeutics Ltd.

Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002

Follow us on

Subscribe to Alerts

IR@Chemomab.com

Barbara Lindheim

Consulting Vice President

Investor & Public Relations

Barbara.Lindheim@Chemomab.com

Phone: +1-917-355-9234

Copyright © Chemomab. All rights reserved.

Privacy Policy Terms of Service

Designed and built by Studio Praktik